Brown Kevin F, Bloomer Zachary W, Shakir Mohamed K M, Cognetti Matthew J, Muir Jeannie M, Hoang Thanh D
Division of Endocrinology, Department of Medicine Walter Reed National Military Medical Center Bethesda Maryland United States.
Division of Endocrinology, Department of Medicine Uniformed Service University of the Health Sciences Bethesda Maryland United States.
Clin Case Rep. 2023 Jun 30;11(7):e7507. doi: 10.1002/ccr3.7507. eCollection 2023 Jul.
When managing patients with differentiated thyroid cancers (DTC) and lytic bone lesions, physicians should consider etiologies other than DTC bony metastases when there is no biochemical and functional radiographic evidence of extensive DTC burden.
Systemic mastocytosis (SM) is a clonal expansion of mast cells associated with an increased risk of solid malignancies. There is no known association between systemic mastocytosis and thyroid cancer. We report a young woman who presented with cervical lymphadenopathy, palpable thyroid nodule, and lytic bone lesions who was diagnosed with papillary thyroid cancer (PTC). The patient's post-surgical thyroglobulin was lower than expected for metastatic thyroid cancer, and the lytic bone lesions did not demonstrate uptake of I. Upon further evaluation, the patient was found to have SM. We report a case of co-occurrence of PTC and SM.
在管理分化型甲状腺癌（DTC）合并溶骨性骨病变的患者时，若没有广泛DTC负荷的生化及功能影像学证据，医生应考虑DTC骨转移以外的病因。
系统性肥大细胞增多症（SM）是肥大细胞的克隆性增殖，与实体恶性肿瘤风险增加相关。系统性肥大细胞增多症与甲状腺癌之间尚无已知关联。我们报告一名年轻女性，她出现颈部淋巴结病、可触及的甲状腺结节和溶骨性骨病变，被诊断为乳头状甲状腺癌（PTC）。患者术后甲状腺球蛋白低于转移性甲状腺癌预期水平，且溶骨性骨病变未显示碘摄取。进一步评估发现该患者患有SM。我们报告一例PTC与SM并存的病例。
Zotero 插件
